Dr. Brian W. Tempest


CSci, CChem, FRSC, BSc, PhD

Editor of the Journal of Generic Medicines, Non Executive Director United Nations Patent Pool & ex CEO Ranbaxy Laboratories

Dr Brian Tempest advises Companies, Banks, Investment Funds, Private Equity & high net worth individuals on their Strategy in Emerging Markets and Developed Markets based on his wide global experience. He has lived in the USA, UK and for 10 years in New Delhi, India.


Brian started working for Ranbaxy Laboratories in 1995 and he held the positions of Regional Director, Company President, Managing Director and Chief Executive Officer until 2005 when Ranbaxy became the 9th largest Global Generic Pharmaceutical Company. He then became Chief Mentor and Vice Chairman. In 2007 when he retired from Ranbaxy he was appointed a Non Executive Director. Brian is an international advisor to MAPE, India an M&A boutique and serves on several Healthcare and Finance Company Boards. Having led a Sensex Nifty 50 Indian blue chip MNC Brian has a valuable insight of doing business in India.


Brian worked for Glaxo from 1985 to 1992.  As Regional Director-Far East he was responsible for Japan, South Korea, Taiwan & China. As Regional Director-Middle East & Africa he had a focus on Saudi Arabia, Egypt, Bangladesh and Nigeria. In total he has worked in the Pharmaceutical Industry for the last 45 years and has managed Healthcare Businesses in North America, South America, Europe, Africa, Middle East, Australasia, China, Japan and India. He has led many sessions at Investor Meetings held around the world from Tokyo to Las Vegas. In addition Brian is a member of the SCRIP Global Awards Panel.


Brian has joined the Governance Board of the United Nations Patent Pool representing the global generic pharmaceutical industry. He also works for the United Nations Committee for Trade & Development (UNCTAD) on various projects.


Brian received a PhD in Chemistry from Lancaster University in 1971 and in 2009 he became Chairman of the Advisory Board for the Lancaster University Management School. He is a Fellow of the Royal Society of Chemistry and a Fellow of the Royal Society of Medicine.


Brian is on the Board of several companies in India – Fortis Healthcare, Glenmark Pharmaceuticals, SRL Diagnostics, Religare Capital Markets and Petainer-Innopac Packaging. He is also on the Board of the following UK companies – Religare Capital Markets Europe, Religare Capital Markets UK and Hale & Tempest Co Ltd. In 2009, Brian was approved by the FSA under Section 59 of the Financial Services and Markets Act 2000. For more details, please refer to Directorships.